CIRCA ANNOUNCES APPOINTMENT OF LEO DOMINGUEZ AS CHIEF STRATEGY OFFICER
November 7, 2019, Toronto, Ontario, Canada. Circa Life Sciences Inc. is pleased to announce the appointment of Leo Dominguez as Chief Strategy officer.
Leo built a direct sales organization at Immunotec Research Ltd. which handled millions a year in nutraceutical sales. Following his passion for technology, he founded BitSent Inc. and BTC Mining Inc. As an early pioneer in cryptocurrencies he built BitSent into the largest national cryptocurrency ATM company in Canada, and built two separate MegaWatt-class cryptomining data centers for BTC Mining.
Leo studied Science at the University of Waterloo, earning a B.Sc., Honors Science with a Biology Minor and Scientific Computing Option.
Prior to Circa, Leo was Chief Strategic Officer of Qualis Cannabis Corp., Leo oversaw and developed many initiatives including: genetics transfers and acquisition, breeding and propagation, adult beverage, pet products, scientific and educational marketing, international CBD/hemp development projects, and domestic cultivation.
“I am delighted to join the team at Circa, I believe the vision they have created for the company is exactly what is required to make it a global leader in the CBD industry. I look forward to being a part of the success of Circa.”
– Leo Dominguez.
Leo joins a diverse team of specialists at Circa, where he will be supported by industry leading scientists, technologists, commodity traders, and sales teams.
“The entire team at Circa is excited to have someone of Leo Dominguez’s stature join Circa. He could have selected any of the biggest companies in the cannabis/cbd industry to join, and we are honored to have been selected. Leo’s experience in Genetics as well as block-chain technology will help guide Circa’s fully integrated business plan which will be monitored from “seed to consumer”.
-Jazz Samra, founder and president of Circa Life Sciences Inc.
About Circa Life Sciences
Circa Life Science Inc is a Canadian based vertically integrated company focused on the CBD industry, including cultivation, processing, manufacturing, extraction and research and development. Circa will be developing and commercializing top quality medically – validated products, and promoting breakthrough research for the newly created CBD Industry in many countries around the world. Our vision is to become a global leader in providing safe and effective cannabinoid products. From product and process innovation to market execution and everything in between, we are driven by a passion for leadership, and a commitment to drive the industry forward.
Certain statements contained in this new release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Circa’s current belief or assumptions as to the outcome and timing of such future events. Actual future results and developments may differ materially. The forward-looking information contained in this press release is made as of the date hereof, and Circa Life Sciences is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward looking-information. The foregoing statements expressly qualify any forward-looking information contained herein. We seek safe harbor.